Skip to Content

Segluromet Approval History

  • FDA approved: Yes (First approved December 19, 2017)
  • Brand name: Segluromet
  • Generic name: ertugliflozin and metformin hydrochloride
  • Dosage form: Tablets
  • Company: Merck & Co., Inc.
  • Treatment for: Diabetes, Type 2

Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.

Development History and FDA Approval Process for Segluromet

DateArticle
Dec 22, 2017Approval FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide